

# SEQUENCE LISTING

<110> MUIR, TOM W.  
 COLE, PHILIP A  
 FRIEDMAN, JEFFREY M.  
 SONDHI, DOLAN  
 SEVERINOV, KONSTANITINE

<120> METHODS OF LIGATING EXPRESSED PROTEINS

<130> 600-1-214CIPB

<140> 09/191,890

<141> 1998-11-13

<150> 60/065,391

<151> 1997-11-13

<150> 60/093,990

<151> 1998-07-24

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 162

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: generated by  
 ligation of two proteins under certain conditions

<400> 1

Met Leu Phe Val Ala Leu Tyr Asp Phe Val Ala Ser Gly Asp Asn Thr

1 5 10 15

Leu Ser Ile Thr Lys Gly Glu Lys Leu Arg Val Leu Gly Tyr Asn His

20 25 30

Asn Gly Glu Trp Ala Glu Ala Gln Thr Lys Asn Gly Gln Gly Trp Val

35 40 45

Pro Ser Asn Tyr Ile Thr Pro Val Gly Cys Leu Glu Lys His Ser Trp

50 55 60

Tyr His Gly Pro Val Ser Arg Asn Ala Ala Glu Tyr Leu Leu Ser Ser

65	70	75	80
Gly Ile Asn Gly Ser Phe Leu Val Arg Glu Ser Glu Ser Ser Pro Gly			
	85	90	95
Gln Arg Ser Ile Ser Leu Arg Tyr Glu Gly Arg Val Tyr His Tyr Arg			
	100	105	110
Ile Asn Thr Ala Ser Asp Gly Lys Leu Tyr Val Ser Ser Glu Ser Arg			
	115	120	125
Phe Asn Thr Leu Ala Glu Leu Val His His His Ser Thr Val Ala Asp			
	130	135	140
Gly Leu Ile Thr Thr Leu His Tyr Pro Ala Pro Lys Arg Gly Ile His			
	145	150	155
			160
Arg Asp			

<210> 2  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Model peptide  
 synthesized by solid phase peptide synthesis.

<220>  
 <221> SITE  
 <222> (11)  
 <223> Xaa(position 11) is aminocaproate.

<220>  
 <223> C-terminal K has a fluorescein moiety off the  
 E-NH2 group.

<400> 2  
 Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys  
 1 5 10

<210> 3  
 <211> 12  
 <212> PRT  
 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Model peptide  
synthesized by solid phase peptide synthesis.

<220>  
<221> SITE  
<222> (11)  
<223> Xaa(position 11) is aminocaproate.

<400> 3  
Cys Glu Asp Asn Glu Tyr Thr Ala Arg Glu Xaa Lys  
1 5 10

<210> 4  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Model peptide  
synthesized by solid phase peptide synthesis.

<220>  
<223> K has a fluorescein moiety off the E-NH2 group; C-  
terminus is an amide group.

<400> 4  
Cys Gly Arg Gly Arg Gly Arg Lys  
1 5

<210> 5  
<211> 8  
<212> PRT  
<213> Unknown

<220>  
<223> Description of Unknown Organism: ligand

<400> 5  
Pro Val Pro Tyr Glu Asn Val Gly  
1 5

<210> 6  
<211> 11

<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Model peptide  
synthesized by solid phase peptide synthesis.

<220>

<223> C-terminus is an amide group.

<400> 6

Pro Pro Ala Tyr Pro Pro Pro Pro Val Pro Lys  
1 5 10

<210> 7

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 7

ccggtcatcg aaggtcggtg cctggagaaa cattcctggt at

42

<210> 8

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 8

catgatacca ggaatgtttc tccaggcaac gaccttcgat-g

41

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: motif within  
linker region

<400> .9

Ile Glu Gly Arg Cys

1

5

<210> 10

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 10

ggatcccctg gtcatatgct ttttgtggca ctctatgatt ttgtg

45

<210> 11

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic  
oligonucleotide

<400> 11

atgtttctcc aggctgttaa cgggggtgat gtagttgctt gg

42